Related Experiment Videos
[Cost-benefit analysis for hepatitis A vaccine].
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|February 22, 2000
Summary
Mass hepatitis A (HA) vaccination offers significant economic benefits. Targeting individuals aged 15-29 years and considering antibody screening for those over 25 optimizes vaccination strategy and cost-effectiveness.
Area of Science:
- Public Health
- Health Economics
- Epidemiology
Context:
- Hepatitis A (HA) poses a significant public health challenge.
- Economic evaluation is crucial for optimizing vaccination strategies.
- Understanding cost-benefit dynamics informs resource allocation for disease prevention.
Purpose:
- To assess the economic benefits of hepatitis A (HA) vaccination.
- To establish a foundation for an effective HA immunization strategy.
- To determine optimal vaccination targets and approaches for maximizing economic returns.
Summary:
- Health economics methods analyzed the cost-benefit ratio and balance points for HA vaccination.
- A benefit-cost ratio (BCR) of 2.53 was observed in Jiangxing City, with an HA incidence rate of 41.15 per ten thousand.
- Screening for HA antibodies before vaccination can reduce costs in populations with over 50% seropositivity.
Impact:
- Mass HA vaccination strategies yield greater economic benefits.
- The ideal vaccination age group is 15 to 29 years.
- Antibody screening prior to vaccination in individuals over 25 is more cost-effective than direct vaccination.